In 2015, Incyte and Agenus both agreed to work on developing and commercializing antibodies GITR and GX40. In a statement early this week, however, the two have announced plans for Incyte to retain rights to solely develop and commercialize the drugs, profits from which could exceed $350 million. Agenus cited streamlined development as the reason for Incyte’s takeover. Agenus will receive a $20 million payout along with %15 of royalties if the antibodies are successful at market. Read the full statement here.